Villamil A, Mullen E, Casciato P, Gadano A

Language: English
References: 39
Page: 273-280
PDF size: 261.41 Kb.

ABSTRACT

Type I interferons are potent cytokines that possess antiviral, immunomodulating and antiproliferative actions. The development of autoimmune hepatitis is a well recognized complication of treatment with alpha IFN in patients with chronic viral hepatitis. Yet, the occurrence in patients under treatment with beta IFN for other indications is controversial and its occurrence often underestimated. We report two cases of severe acute autoimmune hepatitis in two patients undergoing therapy with IFN beta 1a for multiple sclerosis who recovered under early immunosuppressive therapy.

REFERENCES

1. Interferons. In: Goodman and Gilman’s eds. The pharmacological basis of therapeutics. 10th Ed. McGraw Hill; 2001: 1332-4.

2. The IFN Beta Multiple Sclerosis Study Group: Interferon beta 1b is effective in relapsing-remitting multiple sclerosis: Clinical results of a multicenter randomized, double blind, placebo controlled trial. Neurology 1993; 43: 655-61.

3. The IFN Beta Multiple Sclerosis Study Group, the University of Columbia MS/MRI Analysis Group. IFN beta 1b in the treatment of MS: Final outcomes of the randomized controlled trial. Neurology 1995; 45: 1277-85.

4. Vial T, Descotes J. Immune-mediated side-effects of cytokines in humans. Toxicology 1995; 105: 31-57.

5. Garcia-Buey L, Garcia-Monzon C, Rodriguez S, Borque MJ, Garcia Sanchez A, Iglesias R, De Castro M, et al. Latent autoimmune hepatitis triggered during IFN therapy in patients with chronic hepatitis C. Gastroenterology 1995; 108: 1770-7.

6. Platanias LC. Mechanisms of type-I and type-II interferonmediated signalling. Nat Rev Immunol 2005; 5: 375-86.

7. Durelli L, Ferrero B, Oggero A, Verdun E, Ghezzi A, Montanari E, Zaffaroni M; Betaferon Safety Trial (BEST) Study Group. Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for MS. Neurology 2001; 57: 1363-70.

8. Durand JM, Kaplanski G, Portal I, Scheiner C, Berland Y, Soubeyrand J. Liver failure due to recombinant alpha interferon. Lancet 1991; 338: 1268-9.

9. Janssen HL, Brouwer JT, Nevens F, Sanchez-Tapias JM, Craxi A, Hadziyannis S. Fatal hepatic decompensation associated with interferon alfa. European concerted action on viral hepatitis (Eurohep). BMJ 1993; 306: 107-8.

10. Sheen IS, Liaw YF, Tai DI, Chu CM. Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis. Gastroenterology 1985; 89: 732-5.

11. Papo T, Marcellin P, Bernuau J, Durand F, Poynard T, Benhamou JP. Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med 1992; 116: 51-3.

12. Borg FA, Isenberg DA. Syndromes and complications of interferon therapy. Curr Opin Rheumatok 2007; 19: 61-6.

13. Burdick LM, Somani N, Somani AK. Type I IFNs and their role in the development of autoimmune diseases. Expert Opin Drug Saf 2009; 8: 459-72.

14. Muratori L, Lenzi M, Cataleta M, Giostra F, Cassani F, Ballardini G, Zauli D, et al. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C. J Hepatol 1994; 21: 199-203.

15. Eddleston AL. Hepatitis C infection and autoimmunity. J Hepatol 1996; 24(2 Suppl.): 55-60.

16. Lunel F. Hepatitis C virus and autoimmunity: fortuitous association or reality? Gastroenterology 1994; 107: 1550-5.

17. Monzani F, Caraccio N, Meucci G, Lombardo F, Moscato G, Casolaro A, Ferdeghini M, et al. Effect of 1-year treatment with interferon-beta1b on thyroid function and autoimmunity in patients with multiple sclerosis. Eur J Endocrinol 1999; 141: 325-31.

18. Caraccio N, Dardano A, Manfredonia F, Manca L, Pasquali L, Iudice A, Murri L, et al. Long-term follow-up of 106 multiple sclerosis patients undergoing interferon-beta 1a or 1b therapy: predictive factors of thyroid disease development and duration. J Clin Endocrinol Metab 2005; 90: 4133-37.

19. Tremlett H. Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for multiple sclerosis. Neurology 2002; 58: 1868.

20. Durelli L, Ferrero B, Oggero A, Verdun E, Ghezzi A, Montanari E, Zaffaroni M. Betaferon Safety Trial Study Group. Thyroid function and autoimmunity during interferon beta-1b treatment: a multicenter prospective study. J Clin Endocrinol Metab 2001; 86: 3525-32.

21. Monzani F, Caraccio N, Dardano A, Ferrannini E Thyroid autoimmunity and dysfunction associated with type I interferon therapy. Clin Exp Med 2004; 3: 199-210.

22. Rotondi M, Oliviero A, Profice P, Mone CM, Biondi B, Del Buono A, Mazziotti G, et al. Occurrence of thyroid autoimmunity and dysfunction throughout a nine month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis. J Endocrinol Invest 1998; 21: 748-52.

23. Byrnes V, Afdhal N, Challies T, Greenstein PE. Drug induced liver injury secondary to interferon-beta (IFNbeta) in multiple sclerosis. Ann Hepatol 2006; 5: 56-9.

24. Tremlett HL, Yoshida EM, Oger J. Liver injury associated with the beta interferons for MS: a comparison between the three products. Neurology 2004; 62: 628-31.

25. Francis GS, Grumser Y, Alteri E, Micaleff A, O’Brien F, Alsop J, Stam Moraga M, et al. Hepatic reactions during treatment of multiple sclerosis with interferonbeta-1a: incidence and clinical significance. Drug Saf 2003; 26: 815-27.

26. Verdun E, Isoardo G, Oggero A, Ferrero B, Ghezzi A, Montanari E, Zaffaroni M, et al. Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases? J Interferon Cytokine Res 2002; 22: 245-55.

27. Speciale L, Saresella M, Caputo D, Ruzzante S, Mancuso R, Calvo MG, Guerini FR, et al. Serum auto antibodies presence in multiple sclerosis patients treated with betainterferon 1a and 1b. J Neurovirol 2000; 6 (Suppl. 2): S57-S61.

28. de Seze J, Canva-Delcambre V, Fajardy I, Delalande S, Stojkovic T, Godet E, Vermersch P. Autoimmune hepatitis and multiple sclerosis: a coincidental association? Mult Sclerosis 2005; 11: 691-3.

29. Yoshida EM, Rasmussen SL, Steinbrecher UP, Erb SR, Scudamore CH, Chung SW, Oger JJ, et al. Fulminant liver failure during interferon beta treatment of multiple sclerosis. Neurology 2001; 56: 1416.

30. Duchini A. Autoimmune hepatitis and interferon beta-1a for multiple sclerosis. Am J Gastroenterol 2002; 97: 767-68.

31. Yoshida EM, Rasmussen SL, Steinbrecher UP, Erb SR, Scudamore CH, Chung SW, Oger JJ, et al. Fulminant liver failure during interferon beta treatment of multiple sclerosis. Erratum in: Neurology 2001; 57: 2153.

32. Stewart DE. Hepatic adverse reactions associated with nefazodone. Can J Psychiatry 2002; 47: 375-77.

33. Bayas A, Rieckmann P Managing the adverse effects of interferon- beta therapy in multiple sclerosis. Drug Saf 2000; 22: 149-59.

34. Tremlett H, Oger J. Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis. J Neurol 2004; 251: 1297-303.

35. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38.

36. Ichai P, Duclos-Vallee JC, Guettier C, Ben Hamida S, Antonini T, Delvart T, Saliba F, et al. Usefulness of Corticosteroids for the Treatment of Severe and Fulminant Forms of Autoimmune Hepatitis. Liv Transplant 2007; 13; 996-1003.

37. Villamil AG, Casciato P, Mullen E, Bustos, Giunta D, Ciardullo M, Bandi M, et al. Fulminant autoimmune hepatitis type I: Clinical presentation, outcome and prognostic factors. Am J Transplant 2005; 5 (Sup 11); 278 (Abs 480).

38. Potts JR, Verma S. Optimizing management in autoimmune hepatitis with liver failure at initial presentation. WJ Gastroenterol 2011; 17:2070-5.

39. Abenavoli L, Milic N, Beaugrand M. Severe hepatitis induced by cyproterone acetate: Role of corticosteroids. A case report. Ann Hepatology 2013; 12: 152-5.